

Supplementary Table S1 Primary and secondary endpoints

	Control		Arm 1		<i>P</i>	Arm 2		<i>P</i>
	Responders	% (95%CI)	Responders	% (95%CI)		Responders	% (95%CI)	
CR by a single-course	NA	NA	34/95	35.8 (26.0-45.1)		43/92	46.7 (35.4-57.1)	
CR by initial drugs*	56/87	64.4 (54.1-74.6)	54/91	59.3 (49.1-70.0)	0.014	82/92	89.1 (82.6-95.7)	<0.001
CR by single drugs*	80/84	95.2 (90.6-99.9)	83/89	93.3 (88.1-98.6)	0.577	NA	NA	0.135 <sup>#</sup>
CR by salvage multi-drugs*	4/84	4.8 (0.1-9.4)	6/89	6.7 (1.4-11.9)		10/92	10.9 (4.4-17.4)	

Note: \* Per-protocol analysis. CR: complete remission; NA: not applicable.

<sup>#</sup> CR rate by single-course and subsequent multi-course of MTX combined with ACTD in Arm2 compared with CR rate by methotrexate and further dactinomycin in the control arm

Supplementary Table S2 Comparison of courses for CR required in different groups (35.8% in arm1 and 46.7% patients in arm2 were excluded for the single-course success)

	Control		Arm 1		<i>P</i>	Arm 2		<i>P</i>
	Median	IQR	Median	IQR		Median	IQR	
CR by initial drugs*	3	2–4	3	3–4	0.374	3.5	3–4	0.016
CR by single drugs*	5	4–6	5	4–6	0.568	NA	NA	
CR by salvage multi-drugs*	7	7–9 <sup>#</sup>	8	7–11 <sup>#</sup>	0.662	7	4–10 <sup>#</sup>	0.513

Note: \* Per-protocol analysis. CR: complete remission; NA: not applicable.

<sup>#</sup> Range, for the small number of patients